摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-isobutoxy-pyridine | 98959-57-0

中文名称
——
中文别名
——
英文名称
3-isobutoxy-pyridine
英文别名
3-Isobutoxy-pyridin;3-(2-Methylpropoxy)pyridine
3-isobutoxy-pyridine化学式
CAS
98959-57-0
化学式
C9H13NO
mdl
——
分子量
151.208
InChiKey
HFZWFMVFKNMMGP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    11
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.44
  • 拓扑面积:
    22.1
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为产物:
    描述:
    3-羟基吡啶 、 alkaline earth salt of/the/ methylsulfuric acid 在 乙醇sodium ethanolate 作用下, 生成 3-isobutoxy-pyridine
    参考文献:
    名称:
    Fuerst; Dietz, Journal fur praktische Chemie (Leipzig 1954), 1957, vol. 4, p. 147,155
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • [EN] NAMPT MODULATORS<br/>[FR] MODULATEURS DE NAMPT
    申请人:CYTOKINETICS INC
    公开号:WO2021159015A1
    公开(公告)日:2021-08-12
    Provided are compounds of Formula (II) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, and p are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (II), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (II), or a pharmaceutically acceptable salt thereof.
    提供了公式(II)的化合物或其药用可接受盐,其中R1、R2、R3、R4、R5、R6和p如本文所定义。还提供了包含公式(II)化合物或其药用可接受盐的药用可接受组合物。还提供了使用公式(II)化合物或其药用可接受盐的方法。
  • Viral Polymerase Inhibitors
    申请人:Beaulieu L. Pierre
    公开号:US20080045516A1
    公开(公告)日:2008-02-21
    Compounds of formula I: wherein X, R 2 , R 3 , R 5 and R 6 are defined herein, are useful as inhibitors of the hepatitis C virus NS5B polymerase.
    式I的化合物: 其中X,R2,R3,R5和R6如本文所定义,可用作乙型肝炎病毒NS5B聚合酶的抑制剂
  • Bicyclic Pyrrole Derivatives
    申请人:Nakahira Hiroyuki
    公开号:US20080318922A1
    公开(公告)日:2008-12-25
    Compounds represented by the general formula (I), prodrugs thereof, or pharmaceutically acceptable salts of both are provided as compounds which have high DPP-IV inhibiting activity and are improved in safety, toxicity and so on: (I) wherein the solid line and dotted line between A 1 and A 2 represents a double bond (A 1 =A 2 ) or the like; A 1 is C(R 4 ) or the like; A 2 is nitrogen atom or the like; R 1 is hydrogen atom, optionally substituted alkyl group, or the like; R 2 is hydrogen atom, optionally substituted alkyl group, or the like; R 3 is hydrogen atom, halogen atom, or the like; R 4 is hydrogen atom, hydroxyl, halogen atom, or the like; and Y is a group represented by the general formula (A) or the like; (A) [wherein m1 is 0, 1, 2 or 3; and the group (A) may be freed from R 6 or substituted with one or two R 6 's which are each independently halogen atom or the like.]
    提供了一种通式(I)、其前药或两者的药物可接受盐作为具有高DPP-IV抑制活性并在安全性、毒性等方面得到改进的化合物:(I)其中A1和A2之间的实线和虚线表示双键(A1=A2)或类似物;A1是C(R4)或类似物;A2是氮原子或类似物;R1是氢原子、可选取代烷基或类似物;R2是氢原子、可选取代烷基或类似物;R3是氢原子、卤原子或类似物;R4是氢原子、羟基、卤原子或类似物;Y是由通式(A)或类似物表示的基团;(A)[其中m1为0、1、2或3;基团(A)可以从R6中释放或用一个或两个R6替代,它们各自独立地是卤原子或类似物。]
  • INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    申请人:Gilead Sciences, Inc.
    公开号:US20130190491A1
    公开(公告)日:2013-07-25
    Compounds of formula I: wherein c, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are defined herein, are useful as inhibitors of HIV replication.
    式I的化合物:其中c,R2,R3,R4,R5,R6,R7和R8如本文所定义,可用作HIV复制的抑制剂
  • NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS
    申请人:Babaoglu Kerim
    公开号:US20130203727A1
    公开(公告)日:2013-08-08
    The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds of formula (I).
    本发明提供了公式(I)的化合物或其盐,如本文所述。本发明还提供了包含公式I化合物的药物组合物,制备公式(I)化合物的过程,用于制备公式I化合物的中间体以及使用公式(I)化合物治疗哺乳动物的HIV病毒增殖,治疗艾滋病或延缓艾滋病或ARC症状发作的治疗方法。
查看更多